ZYBERNO
Stock Report
Updated Aug 29, 2026

ROIVANT SCIENCES LTD. (ROIV)

Healthcare • NASDAQ

$36.01
Roivant Sciences Ltd. is a Swiss-American biopharmaceutical company headquartered in Basel, Switzerland and New York City, that develops and commercializes medicines through its portfolio of companies called 'Vants.' The company's key assets include Immunovant (FcRn inhibitor batoclimab), Kiniksa Pharmaceuticals, and a development pipeline across immunology, oncology, and other therapeutic areas.

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
30.0/100
WEAK BUSINESS
ROIVANT SCIENCES LTD. (ROIV) scores 30/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-12.1%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.04x)
Operating Margin (Operational Efficiency):CRITICAL (-15,763.3%)
Return on Capital (Capital Efficiency):CRITICAL (-75.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ROIVANT SCIENCES LTD. (ROIV) stock report — Zyberno Score 30/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, ROIV generated -$823.38M in Owner Earnings. Capital was deployed as follows: $206.73M returned via share buybacks, $4.59M invested in capital expenditures. Reinvestment rate: 1.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:36.01
Market Cap:$25.96B

Valuation Multiples (3)

P/B Ratio:5.27x
P/S Ratio:3,445.99x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$22.22B

Price Action & Momentum (3)

Momentum Percentile:97 / 100
% of 52-Week High:94.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-11.3%
Reinvestment Rate:1.0%
Fundamental Growth Rate (g):-0.8%

Margin Analysis (3)

Operating Margin Ttm:-15,763.3%
Net Margin Ttm:-8,007.5%
Ebitda Margin:-15,507.6%

TTM Performance (2)

Operating Margin Ttm:-15,763.3%
Net Margin Ttm:-8,007.5%

Yield Metrics (2)

Earnings Yield:-$2.69
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:3.2%
Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-45.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:16.72x
Quick Ratio:16.72x
Cash Ratio:13.55x

Leverage Analysis (3)

Debt To Equity Ttm:0.04x
Debt-to-Equity Ratio:0.04x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:4,458,477,000.00
Cash And Cash Equivalents:3,842,082,000.00
Long Term Debt:$94.77M
Net Debt:-$3.73B
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $7.53M
Linear Growth: -45.0%
📊 Click to view full ROIV Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$1.19B

Bottom Line Performance (3)

-$603.13M
Income Before Tax:-$718.19M
Ebitda Ttm:-1,168,035,000.00

Operating Expenses (5)

Operating Expenses:1,374,298,000.00
R And D Expense:730,909,000.00
Sga Expense:641,974,000.00
Income Tax Expense:$124.72M
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:50,687.2%
Sga To Revenue Percentage:44,519.7%
Ebitda Margin:-15,507.6%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$5.31B
Current Assets:$4.74B
Ppe Net:11,320,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:384,624,000.00
Current Liabilities:283,603,000.00
Long Term Debt:$94.77M
Short Term Debt:$12.38M

Equity & Capital (3)

Equity:$4.92B
Retained Earnings:-$900.35M
Common Stock:7,000,000,000.00

Working Capital Items (3)

Accounts Receivable:678,000.00
Inventory:0.00
Accounts Payable:168,740,000.00

Special Items (2)

Contract Liabilities:3,050,000.00
Stock Based Compensation:83,342,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$816.47M-$821.06M

Investment Activities (2)

Investing Cash Flow:$281.26M
Capital Expenditures Ttm:4,593,000.00

Financing Activities (3)

Financing Cash Flow:-$181.51M
Dividends Paid Ttm:0.00
Stock Repurchase:206,729,000.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:19,259,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.86
-$0.97
Earnings Per Share Ttm:-$0.84

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.01
Operating Cash Flow Per Share:-$1.04

Book Value & Capital (2)

Book Value Per Share:$6.83
Cash Per Share:5.33

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.00x
Working Capital Turnover Ttm:0.00x

Receivables Management (2)

Receivables Turnover Ttm:11.11x
Days Sales Outstanding Ttm:32.86

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:8,177.12
Cash Conversion Cycle:-9,143.27
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$823.38M

Damodaran Growth Analysis (2)

Reinvestment Rate:1.0%
Fundamental Growth Rate (g):-0.8%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-45.0%

Other Growth Rates (1)

Book Value Growth Rate (Linear):44.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:ROIV
Company Name:ROIVANT SCIENCES LTD.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:720.78M
Shares Outstanding Basic:720.78M
Shares Outstanding Diluted:720.78M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-29 00:54:22 UTC
Data Timestamp:2026-08-29T00:54:22.240232
Scroll to Top